India, March 10 -- Biodexa Pharmaceuticals PLC (BDRX), a clinical stage biopharmaceutical company, Monday announced results of its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the protocol for the registrational Phase 3 study of eRapa in familial adenomatous polyposis (FAP). The company's shares are trading more than 20 percent at $3.76.
FAP is an inherited condition causing numerous polyps in the colon and rectum.
The company noted that the meeting has cleared the way for the registrational Phase 3 study in FAP in the U.S. next quarter. The study is expected to be conducted in about 30 sites across the US and Europe.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
"With ...